New England Journal of Medicine Publishes Positive Phase 3 VALOR Trial Results of Brepocitinib in Dermatomyositis
Priovant Therapeutics, a Roivant company, reported positive Phase 3 trial results for brepocitinib in dermatomyositis, showing statistically significant improvements over placebo in multiple efficacy endpoints including muscle strength, skin disease, physical function, and corticosteroid reduction. Results were published in the New England Journal …